XORTX Therapeutics (FRA:ANU) Cyclically Adjusted FCF per Share: €-6.78 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ANU XORTX Therapeutics Inc FRA:ANU
39 GF Score
Price €1.71
! 1 Warning Sign
View Full Analysis

What is XORTX Therapeutics Cyclically Adjusted FCF per Share?

XORTX Therapeutics FRA:ANU -7.26% 39 Cyclically Adjusted FCF per Share is €-6.78 as of Mar. 2026. GuruFocus rates FRA:ANU with a GF Score™ of 39/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

XORTX Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.313. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-6.78 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-09), XORTX Therapeutics's current stock price is €1.712. XORTX Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-6.78. XORTX Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


XORTX Therapeutics  (FRA:ANU) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


XORTX Therapeutics Cyclically Adjusted FCF per Share Related Terms


XORTX Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for XORTX Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XORTX Therapeutics Cyclically Adjusted FCF per Share Chart

XORTX Therapeutics Annual Data
Trend Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -10.42 -8.27

XORTX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.29 -9.74 -8.75 -8.27 -6.78

FRA:ANU vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, XORTX Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:ANU
39GF Score
XORTX Therapeutics Inc FRA:ANU
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XORTX Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XORTX Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.313/132.2623*132.2623
=-0.313

Current CPI (Mar. 2026) = 132.2623.

XORTX Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201605 -0.741 101.765 -0.963
201608 -0.148 101.686 -0.193
201611 -2.828 101.607 -3.681
201702 -0.658 102.476 -0.849
201705 -0.921 103.108 -1.181
201708 -1.263 103.108 -1.620
201711 -0.684 103.740 -0.872
201803 -5.679 105.004 -7.153
201806 -1.403 105.557 -1.758
201809 -1.286 105.636 -1.610
201812 -0.261 105.399 -0.328
201903 -0.595 106.979 -0.736
201906 -0.235 107.690 -0.289
201909 0.084 107.611 0.103
201912 -0.622 107.769 -0.763
202003 -9.687 107.927 -11.871
202006 -1.149 108.401 -1.402
202009 -0.695 108.164 -0.850
202012 6.110 108.559 7.444
202103 -4.257 110.298 -5.105
202106 -2.875 111.720 -3.404
202109 -0.100 112.905 -0.117
202112 -10.175 113.774 -11.828
202203 -7.879 117.646 -8.858
202206 -6.225 120.806 -6.815
202209 -3.401 120.648 -3.728
202212 -8.409 120.964 -9.194
202303 -6.062 122.702 -6.534
202306 -4.013 124.203 -4.273
202309 -2.528 125.230 -2.670
202312 -2.998 125.072 -3.170
202403 -2.475 126.258 -2.593
202406 -1.193 127.522 -1.237
202409 -1.203 127.285 -1.250
202412 -1.298 127.364 -1.348
202503 -0.802 129.181 -0.821
202506 -0.933 129.892 -0.950
202509 -0.557 130.287 -0.565
202512 -0.474 130.366 -0.481
202603 -0.313 132.262 -0.313

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-6.78 mean?
XORTX Therapeutics (FRA:ANU) has a Cyclically Adjusted FCF per Share of €-6.78 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on XORTX Therapeutics and its competitors.
Is XORTX Therapeutics' Cyclically Adjusted FCF per Share too high?
XORTX Therapeutics' current Cyclically Adjusted FCF per Share is €-6.78. Overall, XORTX Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does XORTX Therapeutics' Cyclically Adjusted FCF per Share compare to VRTX and REGN?
XORTX Therapeutics' Cyclically Adjusted FCF per Share of €-6.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on XORTX Therapeutics and its competitors. XORTX Therapeutics's current Cyclically Adjusted FCF per Share is €-6.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XORTX Therapeutics stock overvalued right now?
XORTX Therapeutics (FRA:ANU) has a current Cyclically Adjusted FCF per Share of €-6.78. The current Cyclically Adjusted FCF per Share is €-6.78. XORTX Therapeutics' overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For XORTX Therapeutics (FRA:ANU), the current Cyclically Adjusted FCF per Share is €-6.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XORTX Therapeutics Business Description

Other Exchanges XRTX:USAXRTX:Canada
Address 3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
39GF Score

Get the complete analysis for FRA:ANU

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.71
Price